Drug delivery polymer and uses thereof

1. A polymer prepared by:

(a) reacting a macromonomer of Formula (III):

or a salt thereof, wherein:

a is an integer from 1 to 10, inclusive;

b is an integer from 1 to 5, inclusive;

c is an integer from 30 to 100, inclusive;

e is 0, 1, 2, 3, or 4;

L is —O—, —S—, —NR La —, —NR La C(═O)—, —C(═O)NR La —, —SC(═O)—, —C(═O)S—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —OC(═O)NR La —, —NR La C(═O)O—, trans-CR Lb ═CR Lb —, cis-CR Lb ═CR Lb —, —C≡C—, —OC(R Lb ) 2 —, —C(R Lb ) 2 O—, —NR La C(R Lb ) 2 —, —C(R Lb ) 2 NR La —, —S(═O) 2 O—, —OS(═O) 2 —, —S(═O) 2 NR—, —NR La S(═O) 2 —, or an optionally substituted C 1-10 hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain is replaced with —O—, —S—, —NR La —, —NR La C(═O)—, —C(═O)NR La —, —SC(═O)—, —C(═O)S—, —OC(═O)O—, —C(═O)O, —OC(═O)O—, —OC(═O)NR La —, —NR La C(═O)O—, trans-CR Lb ═CR Lb —, cis-CR Lb ═CR Lb —, —C≡C—, —OC(R Lb ) 2 —, —C(R Lb ) 2 O—, —NR La C(R Lb ) 2 —, —C(R Lb ) 2 NR La —, —S(═O) 2 O—, —OS(═O) 2 —, —S(═O) 2 NR La —, or —NR La S(═O) 2 —, wherein each instance of R La is independently hydrogen, optionally substituted C 1-10 alkyl, or a nitrogen protecting group, and wherein each occurrence of R Lb is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R Lb groups are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring, or R La and R Lb are joined to form an optionally substituted heterocyclic ring; and

M is hydrogen, or a therapeutic, diagnostic, or prophylactic agent;

with a metathesis catalyst to form a polymerization mixture; and

(b) mixing the polymerization mixture from step (a) with a solution of a platinum complex of Formula (I):

or a salt thereof, wherein:

X 1 is F, Cl, Br, or I;

X 2 is F, Cl, Br, or I;

each instance of R N1 and R N2 is independently hydrogen, optionally substituted C 1-6 alkyl, or a nitrogen protecting group; or two R N1 are taken with the intervening atoms to form a heterocyclic ring; or two R N2 are taken with the intervening atoms to form a heterocyclic ring; or R N1 and R N2 are taken with the intervening atoms to form a heterocyclic ring; and

n is 1, 2, 3, 4, 5, or 6.

2. The polymer of claim 1 , wherein the amount of the macromonomer, platinum complex, and metathesis catalyst is of the molar ratio m:N:1, wherein m is an integer from 1 to 20, inclusive; and N is an integer from 1 to 20, inclusive.

3. A polymer prepared by:

(a) reacting a first macromonomer of Formula (III):

or a salt thereof, wherein:

a is an integer from 1 to 10, inclusive;

b is an integer from 1 to 5, inclusive;

c is an integer from 30 to 100, inclusive;

e is 0, 1, 2, 3, or 4;

L is —O—, —S—, —NR La —, —NR La C(═O)—, —C(═O)NR La —, —SC(═O)—, —C(═O)S—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —OC(═O)NR La —, —NR La C(═O)O—, trans-CR Lb ═CR Lb —, cis-CR Lb ═CR Lb —, —C≡C—, —OC(R Lb ) 2 —, —C(R Lb ) 2 O—, —NR La C(R Lb ) 2 —, —C(R Lb ) 2 NR La —, —S(═O) 2 O—, —OS(═O) 2 —, —S(═O) 2 NR—, —NR La S(═O) 2 —, or an optionally substituted C 1-10 hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain is replaced with —O—, —S—, —NR La —, —NR La C(═O)—, —C(═O)NR La —, —SC(═O)—, —C(═O)S—, —OC(═O)O—, —C(═O)O, —OC(═O)O—, —OC(═O)NR La —, —NR La C(═O)O—, trans-CR Lb ═CR Lb —, cis-CR Lb ═CR Lb —, —C≡C—, —OC(R Lb ) 2 —, —C(R Lb ) 2 O—, —NR La C(R Lb ) 2 —, —C(R Lb ) 2 NR La —, —S(═O) 2 O—, —OS(═O) 2 —, —S(═O) 2 NR La —, or —NR La S(═O) 2 —, wherein each instance of R La is independently hydrogen, optionally substituted C 1-10 alkyl, or a nitrogen protecting group, and wherein each occurrence of R Lb is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R Lb groups are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring, or R La and R Lb are joined to form an optionally substituted heterocyclic ring; and

M is hydrogen, or a therapeutic, diagnostic, or prophylactic agent;

with a second macromonomer of Formula (III) in the presence of a metathesis catalyst to form a polymerization mixture; wherein M of the first macromonomer is different from M of the second macromonomer; and

(b) mixing the polymerization mixture from step (a) with a solution of a platinum complex of Formula (I):

or a salt thereof, wherein:

X 1 is F, Cl, Br, or I;

X 2 is F, Cl, Br, or I;

each instance of R N1 and R N2 is independently hydrogen, optionally substituted C 1-6 alkyl, or a nitrogen protecting group; or two R N1 are taken with the intervening atoms to form a heterocyclic ring; or two R N2 are taken with the intervening atoms to form a heterocyclic ring; or R N1 and R N2 are taken with the intervening atoms to form a heterocyclic ring; and

n is 1, 2, 3, 4, 5, or 6.

4. A pharmaceutical composition comprising a polymer of claim 1 and a pharmaceutically acceptable excipient.

5. A kit comprising a polymer of claim 1 , and instructions for use thereof.

6. A method of preparing a polymer of claim 1 comprising:

(a) oxidizing a compound of Formula (s-1):

with an oxidant to form a platinum hydroxide of Formula (s-2):

(b) coupling the platinum hydroxide of Formula (s-2) with a compound of Formula (s-3):

to form a platinum complex of Formula (I):

wherein:

X 1 is F, Cl, Br, or I;

X 2 is F, Cl, Br, or I;

each instance of R N1 and R N2 is independently hydrogen, optionally substituted C 1-6 alkyl, or a nitrogen protecting group; or two R N1 are taken with the intervening atoms to form a heterocyclic ring; or two R N2 are taken with the intervening atoms to form a heterocyclic ring; or R N1 and R N2 are taken with the intervening atoms to form a heterocyclic ring; and

n is 1, 2, 3, 4, 5, or 6;

(c) reacting a macromonomer of Formula (III):

with a metathesis catalyst to form a polymerization mixture, wherein:

a is an integer from 1 to 10, inclusive;

b is an integer from 1 to 5, inclusive;

c is an integer from 30 to 100, inclusive;

e is 0, 1, 2, 3, or 4;

L is —O—, —S—, —NR La —, —NR La C(═O)—, —C(═O)NR La —, —SC(═O)—, —C(═O)S—, —OC(═O)—, —C(═O)O—, —OC(═O)O—, —OC(═O)NR La —, —NR La C(═O)O—, trans-CR Lb ═CR Lb —, cis-CR Lb ═CR Lb —, —C≡C—, —OC(R Lb ) 2 —, —C(R Lb ) 2 O—, —NR La C(R Lb ) 2 —, —C(R Lb ) 2 NR La —, —S(═O) 2 O—, —OS(═O) 2 —, —S(═O) 2 NR—, —NR La S(═O) 2 —, or an optionally substituted C 1-10 hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain is replaced with —O—, —S—, —NR La —, —NR La C(═O)—, —C(═O)NR La —, —SC(═O)—, —C(═O)S—, —OC(═O)O—, —C(═O)O, —OC(═O)O—, —OC(═O)NR La —, —NR La C(═O)O—, trans-CR Lb ═CR Lb —, cis-CR Lb ═CR Lb —, —C≡C—, —OC(R Lb ) 2 —, —C(R Lb ) 2 O—, —NR La C(R Lb ) 2 —, —C(R Lb ) 2 NR La —, —S(═O) 2 O—, —OS(═O) 2 —, —S(═O) 2 NR La —, or —NR La S(═O) 2 —, wherein each instance of R La is independently hydrogen, optionally substituted C 1-10 alkyl, or a nitrogen protecting group, and wherein each occurrence of R Lb is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R Lb groups are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring, or R La and R Lb are joined to form an optionally substituted heterocyclic ring; and

M is hydrogen or a therapeutic, diagnostic, or prophylactic agent; and

(d) mixing the platinum complex of Formula (I) from step (b) with the polymerization mixture from step (c) to yield a polymer of claim 1 .

7. The polymer of claim 1 , wherein L is an optionally substituted C 1-10 hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain is replaced with —O—, —NR La C(═O)—, —C(═O)NR La —, —OC(═O)—, —C(═O)O—, —OC(═O)O—, trans-CR Lb ═CR Lb —, cis-CR Lb ═CR Lb —, —OC(R Lb ) 2 —, —C(R Lb ) 2 O—, —S(═O) 2 O—, or −OS(═O) 2 —.

8. The polymer of claim 1 , wherein L is of the formula:

wherein:

p is an integer from 1 to 10, inclusive;

q is an integer from 1 to 10, inclusive;

each instance of R E is halogen, —CN, —NO 2 , —N 3 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted phenyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —OR A , —N(R B ) 2 , —SR A , —C(═O)R A , —C(═O)OR A , —C(═O)SR A , —C(═O)N(R B ) 2 , —C(═O)N(R B )N(R B ) 2 , —OC(═O)R A , —OC(═O)N(R B ) 2 , —NR B C(═O)R A , —NR B C(═O)N(R B ) 2 , —NR B C(═O)N(R B )N(R B ) 2 , —NR B C(═O)OR A , —SC(═O)R A , —C(═NR B )R A , —C(═NNR B )R A , —C(═NOR A )R A , —C(═NR B )N(R B ) 2 , —NR B C(═NR B )R B , —C(═S)R A , —C(═S)N(R B ) 2 , —NR B C(═S)R A , —S(═O)R A , —OS(═O) 2 R A , —SO 2 R A , —NR B SO 2 R A , or —SO 2 N(R B ) 2 ;

each R A is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

each R B is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R B groups are taken together with their intervening atoms to form an optionally substituted heterocyclic ring;

each k is independently 0, 1, 2, 3, or 4;

g is an integer from 1 to 10, inclusive; and

h is an integer from 1 to 10, inclusive.

9. The polymer of claim 8 , wherein L is of the formula:

10. The polymer of claim 8 , wherein L is of the formula:

11. The polymer of claim 8 , wherein L is of the formula:

12. The polymer of claim 8 , wherein L is of the formula:

13. The polymer of claim 8 , wherein L is of the formula:

14. The polymer of claim 8 , wherein L is of the formula:

15. The polymer of claim 1 , further wherein L is cleavable by reduction or by hydrolysis or is photo-cleavable.

16. The polymer of claim 1 , wherein M is hydrogen.

17. The polymer of claim 1 , wherein M is a therapeutic agent, prophylactic agent, or diagnostic agent.

18. The polymer of claim 1 , wherein M is of the formula:

19. The polymer of claim 1 , wherein the macromonomer is of the formula:

or a salt thereof.

20. The polymer of claim 1 , wherein e is 1, 2, 3, or 4.

21. The polymer of claim 20 , wherein M is a therapeutic agent.

22. A method of treating a proliferative disease comprising administering or implanting to a subject in need thereof a therapeutically effective amount of the polymer of claim 21 .

23. The polymer of claim 20 , wherein M is an anti-cancer agent.

24. The method of claim 22 , wherein the proliferative disease is cancer.

25. The method of claim 22 , wherein the proliferative disease is lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, large bowel cancer, biliary tract cancer, liver cancer, kidney cancer, prostate cancer, breast cancer, pancreas cancer, or endometrial cancer.

26. The method of claim 22 , wherein the proliferative disease is benign neoplasm.

27. The method of claim 22 , wherein the proliferative disease is an inflammatory disease, autoinflammatory disease, or autoimmune disease.

28. The method of claim 22 further comprising administering or implanting to the subject in need thereof an additional pharmaceutical agent.

29. The method of claim 28 , wherein the additional pharmaceutical agent is an anti-cancer agent.

30. The polymer of claim 3 , wherein e is 1, 2, 3, or 4.

31. The polymer of claim 30 , wherein M is a therapeutic agent.

32. The polymer of claim 30 , wherein M is an anti-cancer agent.

33. A pharmaceutical composition comprising a polymer of claim 21 and a pharmaceutically acceptable excipient.

34. A kit comprising a polymer of claim 3 , and instructions for use thereof.

35. A method of treating a proliferative disease comprising administering or implanting to a subject in need thereof a therapeutically effective amount of the polymer of claim 31 .